Hims & Hers (HIMS.US), a company specializing in selling compounded medications, is experiencing an approximately 8% decline today following a court's rejection of a preliminary injunction request concerning the FDA's decision to remove Zepbound (Eli Lilly's weight-loss drug) from the shortage list.
Under U.S. law, companies can offer copycat versions of brand-name drugs as long as they remain on the shortage list. Therefore, the FDA’s decision has significantly limited the operations of such companies, leading the Outsourcing Facilities Association (OFA) to file a lawsuit against the FDA.
The court’s decision to deny OFA’s request for a preliminary injunction, which would have allowed companies to continue producing lower-cost drug alternatives, is a negative signal for the sector. This is reflected in Hims & Hers' stock price, which has dropped to its lowest level since early February 2025.
The FDA’s decision already led to an 11% decline in Hims & Hers’ stock in December. Today, its shares are down nearly 8%.Source: xStation
US Open: Inflasi AS 4,2%, Nasdaq Berusaha Stabil
Oracle Jadi Ujian Baru Reli AI di Nasdaq
Rotasi Dana ke Healthcare dan Finansial Menguat
Nasdaq Anjlok, Saham AI Tertekan
Perdagangan Berjangka mengandung risiko kerugian. Materi ini hanya untuk tujuan informasi dan bukan merupakan nasihat investasi. Kinerja masa lalu tidak menjamin hasil di masa mendatang. Investasi memiliki risiko. Berinvestasilah dengan bijak. XTB Indonesia berizin dan diawasi oleh Bappebti, OJK dan BI.
